Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in High Risk Non-muscle-Invasive Bladder Cancer Unresponsive to BCG
NCT02625961Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Merck & Co. Primary endpoints: Complete Response Rate of High-Risk Non-Muscle Invasive Bladder Cancer at 6 months, 12-month Disease-Free Survival Rate of High-Risk NMIBC and 2 more. Started Feb 2016; status: terminated.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02625961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625961.